Controlled release melatonin (Circadin®) in the treatment of insomnia in older patients: Efficacy and safety in patients with history of use and non-use of hypnotic drugs

Nava Zisapel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Circadin® is a prolonged-release 2mg melatonin formulation which, when taken before bedtime, mimics the physiological pattern of the endogenous hormone excreted during the night. It was approved by the EU-EMEA in June 2007 for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 or over. Placebo controlled clinical trials demonstrated, beyond the shortening of sleep latency seen with traditional hypnotics, concomitant improvements in sleep quality and next day alertness and subsequently, quality of life. In contrast to traditional sedative hypnotics, CircadinR has shown no evidence of impairing cognitive and psychomotor skills, of rebound, dependence or abuse potential and no significant adverse events compared to placebo. It can be used concomitantly with most medications but may potentiate the effects of GABA-A receptor modulators. Analyses presented here show that Circadin® has comparable efficacy and safety in patients with and without history of hypnotic drug use.

Original languageEnglish
Pages (from-to)337-341
Number of pages5
JournalHarefuah
Volume148
Issue number5
StatePublished - May 2009

Fingerprint

Dive into the research topics of 'Controlled release melatonin (Circadin®) in the treatment of insomnia in older patients: Efficacy and safety in patients with history of use and non-use of hypnotic drugs'. Together they form a unique fingerprint.

Cite this